| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/DIA.2011.0012 |
| P698 | PubMed publication ID | 21854192 |
| P2093 | author name string | Wenhui Zhang | |
| Donna Kowalski | |||
| Sally Klasen | |||
| Sherwyn L Schwartz | |||
| Wim Wilpshaar | |||
| Bola Akinlade | |||
| P433 | issue | 12 | |
| P921 | main subject | patient | Q181600 |
| pharmacokinetics | Q323936 | ||
| pharmacodynamics | Q725307 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1219-1227 | |
| P577 | publication date | 2011-08-19 | |
| P1433 | published in | Diabetes technology & therapeutics | Q26853929 |
| P1476 | title | Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. | |
| P478 | volume | 13 |
| Q38707493 | A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development |
| Q93008518 | A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor |
| Q98567781 | Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis |
| Q38260349 | Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin |
| Q36221586 | Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes |
| Q34664870 | Discontinued in 2013: diabetic drugs |
| Q40091881 | Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study |
| Q57212554 | Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial |
| Q43755014 | Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. |
| Q36756191 | Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study |
| Q41579741 | Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse |
| Q38151450 | Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus |
| Q38154186 | Industrial natural product chemistry for drug discovery and development. |
| Q38340949 | Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes |
| Q43165555 | Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study |
| Q35049845 | Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan |
| Q34412028 | Ipragliflozin: first global approval |
| Q46207930 | Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus |
| Q38285582 | Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus |
| Q35558413 | Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial. |
| Q34407893 | Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus |
| Q36782790 | Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes |
| Q35906490 | SGLT-2 Inhibitors: A New Mechanism for Glycemic Control |
| Q38176145 | SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem |
| Q45348074 | Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes |
| Q37468469 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus |
| Q37468412 | Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus |
| Q50955369 | Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment |
| Q50924878 | Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus |
| Q28072765 | Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects |
| Q50939956 | The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor |
| Q38126109 | The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors |
| Q38908779 | The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes |
| Q36828139 | The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study |
Search more.